Acute Heart FailureKorHF-IIINCT04329234
Korean Heart Failure Registry III
An observational study of Acute Heart Failure, run by Seoul National University Bundang Hospital at 1 site in South Korea.
Trial summary
KorHF III is a multi-center, nationwide, prospective registry of the Korean Society of Heart Failure, which enrolls patients with acute heart failure in Korea. The aim of this registry is to analyze the etiology, treatment, treatment, and prognosis to develop strategies for managing acute heart failure. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Heart Failure
- How many people
- 10,000 participants
- Where
- 1 siteSouth Korea
- Study dates
- 1 Oct 2018to 31 Dec 2027
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with acute heart failure
Who may be able to join
- Symptoms of heart failure
- Signs of heart failure
- Lung congestion in Chest-x-ray
- Objective finding of structural and/or functional disorder of the heart or elevated natriuretic peptide levels
Who cannot join
- Patients younger than 18 years old
- Patients who do no consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea1 site, 1 recruiting
- Recruiting
Seoul National University Bundang Hospital
Seongnam, 463707
Dong-Ju Choi, MD, PhD, 82-31-787-7007, djchoi@snubh.org
Jin Joo Park, MD, 82-31-787 ext. 7074, jinjooparkmd@gmail.com
About this study
Official title: Korean Heart Failure Registry Ⅲ of Korean Society of Heart Failure
KorHF III is a multi-center, nationwide, prospective registry of the Korean Society of Heart Failure, which enrolls patients with acute heart failure in Korea.
The aim of this registry is to analyze the etiology, treatment, treatment, and prognosis to develop strategies for managing acute heart failure.
- Conditions
- Acute Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| acute heart failure | Patients with acute heart failure |
What is being measured
The primary outcome is the main question the study is designed to answer.
In-hospital mortality
In-hospital mortality
Measured: 5 years
Post-discharge mortality
Post-discharge mortality
Measured: 5 years
Post-discharge re-hospitalization
Post-discharge re-hospitalization
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Apr 2020
- Study start1 Oct 2018
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Acute Heart FailureStudies of the same condition, open and under way.
- More trials run by Seoul National University Bundang HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 10,000 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Seoul National University Bundang Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Korean Society of Heart Failure
- Responsible party
- Principal investigator, Dong-Ju Choi, Seoul National University Bundang Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04329234
- Sponsor's protocol ID
- KorHF-III
- Acronym
- KorHF-III
- Status last verified
- Mar 2020
- First submitted
- 30 Mar 2020
- Last updated
- 1 Apr 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Kwon O, Yoon M, Park JJ. Obesity paradox in heart failure with and without diabetes mellitus: a retrospective cohort study : Obesity paradox and DM in HF. Clin Res Cardiol. 2026 Sep 8. doi: 10.1007/s00392-026-03007-0. Online ahead of print.
PubMed 42709147Lee H, Kim EJ, Han SW, Park SM, Kim HS, Cho MC, Ahn HS, Shin MS, Hwang SJ, Jeong JO, Yang DH, Hyun J, Choi JO, Lee HY, Yoo BS, Kang SM, Choi DJ, Cho HJ; KorHF III Investigators. Acute Heart Failure Across the Ejection Fraction Spectrum: Phenotypes, Management, and Outcomes From Nationwide KorHF III Registry. Int J Heart Fail. 2025 Nov 26;8(1):43-55. doi: 10.36628/ijhf.2025.0061. eCollection 2026 Jan.
PubMed 41696058Yoon M, Kim EJ, Han SW, Park SM, Kim IC, Cho MC, Ahn HS, Shin MS, Hwang SJ, Jeong JO, Yang DH, Kim JJ, Choi JO, Cho HJ, Yoo BS, Kang SM, Choi DJ. The Third Nationwide Korean Heart Failure III Registry (KorHF III): The Study Design Paper. Int J Heart Fail. 2024 Apr 1;6(2):70-75. doi: 10.36628/ijhf.2024.0001. eCollection 2024 Apr.
PubMed 38694931
Study at a glance
From the registry record, last updated by the sponsor on 1 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Korean Heart Failure Registry Ⅲ of Korean Society of Heart Failure
- ClinicalTrials.gov ID
- NCT04329234
- Acronym / sponsor ID
- KorHF-III / KorHF-III
- Conditions
- Acute Heart Failure
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- Seoul National University Bundang HospitalUniversity, hospital or other
- Collaborators
- Korean Society of Heart Failure
- Study start
- 1 Oct 2018 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 1 Apr 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
KorHF III is a multi-center, nationwide, prospective registry of the Korean Society of Heart Failure, which enrolls patients with acute heart failure in Korea.
The aim of this registry is to analyze the etiology, treatment, treatment, and prognosis to develop strategies for managing acute heart failure.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| acute heart failure | – | –Patients with acute heart failure |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with acute heart failure
Key inclusion criteria (4 listed)
- Symptoms of heart failure
- Signs of heart failure
- Lung congestion in Chest-x-ray
- Objective finding of structural and/or functional disorder of the heart or elevated natriuretic peptide levels
Key exclusion criteria (2 listed)
- Patients younger than 18 years old
- Patients who do no consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
In-hospital mortality
Time frame: 5 years
In-hospital mortality
Post-discharge mortality
Time frame: 5 years
Post-discharge mortality
Post-discharge re-hospitalization
Time frame: 5 years
Post-discharge re-hospitalization
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Apr 2020.
- Derived from this study: PubMed 42709147Kwon O, Yoon M, Park JJ. Obesity paradox in heart failure with and without diabetes mellitus: a retrospective cohort study : Obesity paradox and DM in HF. Clin Res Cardiol. 2026 Sep 8. doi: 10.1007/s00392-026-03007-0. Online ahead of print.
- Derived from this study: PubMed 41696058Lee H, Kim EJ, Han SW, Park SM, Kim HS, Cho MC, Ahn HS, Shin MS, Hwang SJ, Jeong JO, Yang DH, Hyun J, Choi JO, Lee HY, Yoo BS, Kang SM, Choi DJ, Cho HJ; KorHF III Investigators. Acute Heart Failure Across the Ejection Fraction Spectrum: Phenotypes, Management, and Outcomes From Nationwide KorHF III Registry. Int J Heart Fail. 2025 Nov 26;8(1):43-55. doi: 10.36628/ijhf.2025.0061. eCollection 2026 Jan.
- Derived from this study: PubMed 38694931Yoon M, Kim EJ, Han SW, Park SM, Kim IC, Cho MC, Ahn HS, Shin MS, Hwang SJ, Jeong JO, Yang DH, Kim JJ, Choi JO, Cho HJ, Yoo BS, Kang SM, Choi DJ. The Third Nationwide Korean Heart Failure III Registry (KorHF III): The Study Design Paper. Int J Heart Fail. 2024 Apr 1;6(2):70-75. doi: 10.36628/ijhf.2024.0001. eCollection 2024 Apr.
- Individual participant dataSharing planned: Undecided
Related trials for Acute Heart Failure
Not yet recruiting
Routine Magnesium Testing and Supplementation in Acute Heart Failure (MAG-HF)
Acute Heart Failure (AHF)
RecruitingPhase 3
Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload
Acute Heart Failure
Recruiting
Evaluation of Fibroscan® Performance in Diagnosing Acute Heart Failure in Patients Presenting to the Emergency Department
Acute Heart Failure (AHF)
RecruitingObservational study
Cardiogenic Shock Working Group Registry
Cardiogenic Shock
RecruitingObservational study
Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure
Heart Failure, Muscle Atrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Heart Failure, run by Seoul National University Bundang Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dong-Ju Choi, MD, PhD (82317877007, djchoi@snubh.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
In-hospital mortality (time frame: 5 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04329234, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2020.